MLYS insider exercises options at $10.20 and sells on 11/13/2025

Q: What did Mineralys Therapeutics (MLYS) insider do on 11/13/2025?

They exercised 15,000 stock options at $10.20 and sold the resulting shares at weighted-average prices of $45.8083 and $46.3554 .

Q: How many MLYS shares were sold and at what prices?

Two sales: 10,115 shares at $45.8083 and 4,885 shares at $46.3554 (weighted averages).

Q: How many MLYS shares and options does the insider hold after the transactions?

They held 0 common shares directly and 17,900 stock options remaining beneficially owned.

Q: What is the exercise price and expiration for the reported MLYS stock option?

The option has an exercise price of $10.20 and expires on 02/13/2035 .

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Mineralys Therapeutics (MLYS) director reports option exercise and same-day sales. On 11/13/2025, the reporting person exercised 15,000 stock options at $10.20 per share, received 15,000 common shares, and sold them in two tranches at weighted-average prices of $45.8083 and $46.3554.

The sales totaled 10,115 shares at $45.8083 and 4,885 shares at $46.3554, resulting in 0 common shares held directly after the transactions. Following the exercise, 17,900 stock options remained beneficially owned, with the option grant expiring on 02/13/2035 and vesting in 12 monthly installments following the grant date.

Insights

Routine Form 4: option exercise with immediate share sales.

The insider exercised 15,000 options at an exercise price of $10.20 on 11/13/2025, then sold the resulting shares in two weighted-average transactions at $45.8083 and $46.3554. The sequence (code M then S) is typical: options convert into shares, which are then sold.

Post-transaction, the insider held 0 common shares directly and retained 17,900 options outstanding, with the grant expiring on 02/13/2035. The filing notes monthly vesting over 12 months from grant; actual liquidity and future sales, if any, would depend on vesting and exercise choices disclosed in future reports.

Insider Trade Summary

Net Seller: 15,000 shares ($689,797)

Net Sell 4 txns

Insider Karydas Daphne

Role Director

Sold 15,000 shs ($690K)

Type	Security	Shares	Price	Value
Exercise	Stock Option	15,000	$0.00	--
Exercise	Common Stock	15,000	$10.20	$153K
Sale	Common Stock	10,115	$45.8083	$463K
Sale	Common Stock	4,885	$46.3554	$226K

Holdings After Transaction: Stock Option — 17,900 shares (Direct); Common Stock — 15,000 shares (Direct)

Footnotes (1)

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.19 to $46.18. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.19 to $46.70. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The stock option vests in 12 monthly installments following the date of grant.

Form 4 Insider Transactions: What Each Field Means →

11/13/2025 - 07:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Karydas Daphne

(Last)

(First)

(Middle)

150 N. RADNOR CHESTER ROAD, SUITE F200

(Street)

RADNOR

19087

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/13/2025		M		15,000	A	$10.2	15,000	D
Common Stock	11/13/2025		S		10,115	D	$45.8083⁽¹⁾	4,885	D
Common Stock	11/13/2025		S		4,885	D	$46.3554⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$10.2	11/13/2025		M			15,000	⁽³⁾	02/13/2035	Common Stock	15,000	$0	17,900	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.19 to $46.18. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.19 to $46.70. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The stock option vests in 12 monthly installments following the date of grant.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Mineralys Therapeutics (MLYS) insider do on 11/13/2025?

They exercised 15,000 stock options at $10.20 and sold the resulting shares at weighted-average prices of $45.8083 and $46.3554.

How many MLYS shares were sold and at what prices?

Two sales: 10,115 shares at $45.8083 and 4,885 shares at $46.3554 (weighted averages).

How many MLYS shares and options does the insider hold after the transactions?

They held 0 common shares directly and 17,900 stock options remaining beneficially owned.

What is the exercise price and expiration for the reported MLYS stock option?

The option has an exercise price of $10.20 and expires on 02/13/2035.

How does the MLYS option vest?

The stock option vests in 12 monthly installments following the date of grant.